Semax Molecular Structure & Chemical Properties

Semax peptide represents a distinctive neuropeptide developed in Russia during the early 1990s, derived from the adrenocorticotropic hormone (ACTH) fragment 4-10. This seven-amino acid peptide has garnered significant attention in preclinical research for its neurotrophic and cognitive enhancement properties, with over 100 published studies examining its mechanisms and effects across multiple neurological research applications. Unlike its parent hormone ACTH, Semax lacks hormonal activity while retaining neuroprotective characteristics, making it a subject of extensive investigation in neuroscience research. The peptide’s unique structure incorporates the ACTH(4-7) fragment combined with the C-terminal tripeptide Pro-Gly-Pro (PGP), contributing to enhanced stability compared to the native hormone fragment.

Chemical Structure

2D molecular structure (Source: PubChem)

Technical Specifications

The peptide’s structure contains multiple proline residues that confer resistance to enzymatic breakdown, a characteristic that distinguishes it from the parent ACTH fragment. The methionine N-terminal amino group and histidine imidazole ring contribute to metal-binding capacity, particularly with copper(II) ions, which may play a role in its neuroprotective mechanisms.

Semax Peptide Mechanism of Action

Semax exerts biological effects through multiple interconnected pathways rather than a single defined receptor target. Current research suggests that BDNF/TrkB signaling activation serves as a primary mechanism underlying its neurotrophic effects, supported by at least four additional pathways that work synergistically to promote neuroprotection and cognitive enhancement.

Primary Cellular Pathways

BDNF/TrkB System Modulation – Neurotrophic Signaling

Research has demonstrated that Semax rapidly increases brain-derived neurotrophic factor (BDNF) levels and activates tropomyosin receptor kinase B (TrkB) signaling in the hippocampus. Studies in rat models revealed:

• 1.4-fold increase in BDNF protein levels within 3 hours following intranasal administration
• 1.6-fold enhancement of TrkB tyrosine phosphorylation
• Three-fold increase in BDNF mRNA expression (exon III)
• Two-fold increase in TrkB mRNA levels

Specific binding sites for Semax peptide have been characterized in rat basal forebrain with a dissociation constant of 2.4 nanomolar, suggesting direct receptor-mediated mechanisms. This BDNF upregulation appears fundamental to cognitive enhancement effects observed in learning and memory studies.

Melanocortin Receptor Interactions

Evidence suggests Semax may interact with melanocortin receptor systems, though the precise binding characteristics remain under investigation. Research indicates:

• Competitive antagonism at melanocortin MC4 and MC5 receptors in vitro and in vivo
• Possible antagonist or partial agonist properties at these receptors
• No antagonistic activity at MC3 receptors observed
• MC1 and MC2 receptor interactions not fully characterized

These melanocortin system interactions may contribute to metabolic and neuromodulatory effects distinct from BDNF pathways.

Monoaminergic System Activation

Studies have documented effects on multiple neurotransmitter systems critical for cognitive function and mood regulation:

• Serotonergic system activation in hippocampal and cortical regions
• Dopaminergic pathway modulation affecting motivation and attention
• Potentiation of D-amphetamine-induced locomotor activity in rat models
• Neurotransmitter balance shifts associated with antidepressant-like effects

The peptide’s influence on these systems appears to occur rapidly following administration and may contribute to observed anxiolytic and stress-attenuating properties.

Enkephalinase Inhibition

Semax has been found to inhibit enzymes involved in the degradation of enkephalins and other endogenous regulatory peptides:

• IC50 value of 10 micromolar for enkephalinase inhibition
• Potential modulation of endogenous opioid peptide activity
• Possible contribution to analgesic effects in electrocutaneous pain models
• Clinical significance of this mechanism remains under investigation

Immune and Vascular Gene Expression Modulation

Genome-wide transcriptome analysis in ischemic stroke models revealed extensive effects on gene expression:

• Enhanced expression of genes encoding immunoglobulins and chemokines
• Modulation of immune cell mobility and activity
• Influence on vascular endothelial growth factor (VEGF) signaling
• Effects on genes regulating intracellular calcium levels and blood vessel formation

Semax Peptide Research Applications & Key Findings

Cerebrovascular and Neuroprotection Research

Ischemic Stroke Models

Extensive research in rat focal cerebral ischemia models has examined Semax’s neuroprotective properties. Key findings include:

• Reduced infarct volume in permanent middle cerebral artery occlusion (pMCAO) models
• Enhanced neurological recovery in functional assessment tests
• Genome-wide transcriptome changes affecting immune and vascular systems
• Increased survival of neurons in penumbral regions following ischemia

Studies using the pMCAO model demonstrated that Semax influenced expression of 96 genes at 3 hours post-occlusion, with effects increasing substantially at 24 hours. The peptide predominantly enhanced genes related to immune response modulation.

Human Clinical Observations in Stroke Patients

Several Russian clinical trials have reported outcomes in acute stroke patients, though many publications remain in Russian language:

• Improved restoration of neurological function when added to conventional stroke therapy
• Enhanced motor performance recovery as measured by British Medical Research Council scale
• Increased Barthel index scores indicating improved functional independence
• Elevated plasma BDNF levels correlated with improved outcomes

A trial involving 110 stroke patients receiving two 10-day courses of 6000 mcg/day intranasal Semax showed significantly increased BDNF levels and accelerated rehabilitation when combined with early mobilization therapy.

Cognitive Enhancement and Memory Research

Learning and Memory Studies

Research in rodent behavioral models has investigated cognitive effects:

• Enhanced performance in conditioned avoidance reactions following single intranasal doses
• Improved spatial memory formation in radial arm maze tests
• Increased selective attention during information reception tasks
• Enhanced memory consolidation in various learning paradigms

Studies using 50 mcg/kg intranasal administration in rats showed maximal cognitive enhancement at 3 hours post-administration, correlating with peak BDNF elevation in hippocampus.

Neurotrophin Gene Expression

Temporal dynamics studies revealed complex gene expression patterns:

• Rapid changes in nerve growth factor (NGF) and BDNF mRNA levels within 20 minutes
• Differential effects across brain regions (hippocampus, frontal cortex, retina)
• Sustained elevation lasting 8 hours for neurotrophin genes
• Region-specific responses suggesting targeted neuroplasticity mechanisms

Stress and Mood Research

Chronic Stress Models

Investigations in unpredictable chronic stress paradigms demonstrated:

• Antidepressant-like effects in forced swim and sucrose preference tests
• Attenuation of behavioral consequences of chronic stress exposure
• Normalization of stress-induced behavioral alterations
• Anxiolytic-like properties in elevated plus maze assessments

The peptide’s effects on stress responses appear mediated through modulation of serotonergic systems and BDNF upregulation in stress-sensitive brain regions.

Metal Ion Toxicity and Oxidative Stress

Copper-Induced Cytotoxicity Protection

Research has examined Semax’s metal-binding capacity and protective effects:

• Formation of stable copper(II) complexes with albumin-like coordination
• Reduced cytotoxicity in neuroblastoma and endothelial cell lines exposed to copper
• Protective effects against lead-induced oxidative damage in rat studies
• Antioxidant properties at lower doses, though dose-dependent effects require clarification

Studies suggest the peptide’s metal-binding characteristics may contribute to neuroprotective mechanisms in conditions involving metal ion dysregulation.

Semax Pharmacokinetics & Metabolism

Absorption & Distribution

Semax exhibits distinctive pharmacokinetic properties for a peptide, with research demonstrating activity via multiple administration routes:

• Intranasal administration results in direct CNS delivery with brain uptake within 15-30 minutes
• Intraperitoneal injection shows systemic distribution and CNS penetration in rat models
• Subcutaneous administration demonstrates bioavailability in preclinical studies
• Specific binding to basal forebrain membranes with nanomolar affinity suggests targeted distribution

Radioligand studies using tritium-labeled Semax revealed time-dependent, specific, and reversible binding to brain tissue membranes, with calcium-dependent binding characteristics. The peptide appears to concentrate in regions rich in BDNF receptors, including hippocampus and basal forebrain.

Metabolism & Elimination

The metabolic fate of Semax remains incompletely characterized, but available evidence indicates:

• Plasma half-life under 30 minutes in rat pharmacokinetic studies
• Rapid clearance from systemic circulation
• Likely degradation through peptidase activity, though specific enzymes not identified
• Metabolic pathways for the Pro-Gly-Pro C-terminal fragment may differ from full peptide

A notable paradox exists between rapid plasma elimination and prolonged biological effects lasting hours to days. This suggests either tissue retention, formation of active metabolites, persistent downstream signaling cascade activation, or combination of these mechanisms.

Excretion Pathways

Limited pharmacokinetic data indicates:

• Probable renal elimination of peptide fragments
• Potential hepatic metabolism contributing to clearance
• No evidence of accumulation in chronic dosing studies in animal models
• Complete excretion kinetics and elimination routes require systematic investigation

The disconnect between short plasma half-life and sustained pharmacodynamic effects represents a key area requiring mechanistic clarification for translational applications.

Semax Research Protocols & Administration

Dosing in Published Research

Research investigations have employed diverse Semax doses depending on species, model, and administration route:

• Rat studies: 50-250 mcg/kg most common range (intranasal); 5-450 mcg/kg intraperitoneal
• Mouse models: 10-100 mcg/kg typical experimental range
• Human clinical trials (Russian): 200-6000 mcg/day intranasal (0.1% to 1% solutions)
• Cell culture: 10-100 micromolar concentrations for in vitro studies

Important: These are experimental doses used in animal studies and controlled clinical research protocols. They cannot be extrapolated to other species due to significant differences in metabolism, pharmacokinetics, receptor expression patterns, peptide degradation rates, and blood-brain barrier permeability. Species-specific factors profoundly influence both efficacy and safety profiles.

Administration Routes in Research

Multiple delivery methods have been investigated in preclinical and clinical settings:

• Intranasal administration – Most common route; enables direct CNS delivery bypassing blood-brain barrier; used in Russian clinical practice
• Intraperitoneal injection – Standard route in rodent research for systemic delivery
• Subcutaneous injection – Applied in some experimental protocols
• Intracerebroventricular injection – Used in mechanistic studies requiring direct CNS delivery

Common Model Organisms

Semax has been studied across multiple species and systems:

• Rats – Primary research model (Wistar strain predominant); majority of mechanistic and behavioral data
• Mice – Used in specific genetic and molecular studies
• Human subjects – Limited to clinical trials conducted primarily in Russia and Eastern Europe
• Cell culture systems – Astrocytes, neuroblastoma cells (SH-SY5Y), endothelial cells (RBE4), primary neuronal cultures

Research Limitations & Regulatory Status

Critical Gaps in Current Evidence

Despite extensive preclinical investigation and limited clinical use in Russia, Semax faces substantial translational barriers that constrain broader research applications and clinical development.

Lack of International Clinical Data

The most significant limitation is the absence of rigorous international clinical trials:

• No published Phase I, II, or III trials in peer-reviewed English-language journals meeting international standards
• Russian clinical trial reports often lack complete methodological details
• Human safety profile inadequately characterized outside Russian medical system
• Optimal human dosing parameters not established through systematic dose-finding studies
• Long-term safety in humans unknown beyond observational data

Mechanistic Understanding Gaps

Fundamental aspects of Semax’s mechanism remain unclear:

• Primary molecular target not definitively identified – no confirmed receptor characterized
• Whether effects are direct receptor-mediated or through secondary signaling cascades uncertain
• Hierarchy and relative contribution of multiple observed pathways incompletely understood
• Active metabolites versus intact peptide contribution to pharmacological effects unknown
• Tissue-specific mechanisms and regional brain selectivity require clarification

Long-Term Safety Considerations

Critical safety questions remain unanswered:

• Chronic administration effects beyond several weeks inadequately studied even in animals
• Potential for tolerance development or receptor desensitization with repeated use unknown
• Interaction potential with medications and other peptides uncharacterized
• Effects on tumor growth or cancer cell proliferation not systematically investigated
• Reproductive toxicity and developmental effects require comprehensive evaluation

Regulatory & Approval Status

FDA Position

Semax has not received United States Food and Drug Administration approval:

• Not approved for any human or veterinary indication in the United States
• Classified as an unapproved and unrecognized drug substance
• Not granted Generally Recognized as Safe (GRAS) status
• Not legally available for medical compounding in U.S. pharmacies
• No Investigational New Drug (IND) applications publicly registered for U.S. clinical trials

International Regulatory Status

Regulatory approval is limited to specific jurisdictions:

• Approved in Russian Federation – included on Russian List of Vital and Essential Drugs (2011)
• Used clinically in Russia and some Eastern European countries for stroke and cognitive disorders
• Not approved by European Medicines Agency (EMA)
• Not approved by other major regulatory authorities (Health Canada, TGA Australia, PMDA Japan)
• Widely sold online internationally as research peptide without medical approval

Research Classification: Semax is available only for laboratory research use in most jurisdictions. It is not intended for human consumption, medical use, or veterinary applications outside approved markets. All research must be conducted under appropriate ethical oversight and regulatory compliance with institutional review board approval where applicable.

References

1. Dolotov, O.V., Karpenko, E.A., Seredenina, T.S., Inozemtseva, L.S., Levitskaya, N.G., Rozyczka, J., Dubynina, E.V., Novosadova, E.V., Andreeva, L.A., Alfeeva, L.Y., Kamensky, A.A., Grivennikov, I.A., Myasoedov, N.F., & Engele, J. (2006). Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. Brain Research, 1117(1), 54-60. PubMed
   
2. Dolotov, O.V., Karpenko, E.A., Inozemtseva, L.S., Seredenina, T.S., Levitskaya, N.G., Zolotarev, Y.A., Kamensky, A.A., Grivennikov, I.A., Engele, J., & Myasoedov, N.F. (2006). Semax, an analogue of adrenocorticotropin (4-10), binds specifically and increases levels of brain-derived neurotrophic factor protein in rat basal forebrain. Journal of Neurochemistry, 97(Suppl 1), 82-86. PubMed
   
3. Medvedeva, E.V., Dmitrieva, V.G., Povarova, O.V., Limborska, S.A., Skvortsova, V.I., Myasoedov, N.F., & Dergunova, L.V. (2014). The peptide semax affects the expression of genes related to the immune and vascular systems in rat brain focal ischemia: genome-wide transcriptional analysis. BMC Genomics, 15, 228. PubMed
   
4. Gusev, E.I., Martynov, M.Y., Kostenko, E.V., Petrova, L.V., Bobyreva, S.N., Morozova, O.G., Burd, S.G., Polyakov, Y.I., Voznesenskaya, T.G., & Aktaeva, L.M. (2018). The efficacy of semax in the treatment of patients at different stages of ischemic stroke. Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova, 118(3), 61-68. PubMed
   
5. Shadrina, M.I., Kolomin, T.A., Agapova, T.Y., Agniullin, Y.V., Shram, S.I., Slominsky, P.A., Limborska, S.A., & Myasoedov, N.F. (2010). Comparison of the temporary dynamics of NGF and BDNF gene expression in rat hippocampus, frontal cortex, and retina under Semax action. Journal of Molecular Neuroscience, 41(1), 30-35. PubMed
   
6. Filippenkov, I.B., Stavchansky, V.V., Denisova, A.E., Yuzhakov, V.V., Sevan’kaeva, L.E., Sudarkina, O.Y., Dmitrieva, V.G., Gubsky, L.V., Myasoedov, N.F., Limborska, S.A., & Dergunova, L.V. (2020). Novel Insights into the Protective Properties of ACTH(4-7)PGP (Semax) Peptide at the Transcriptome Level Following Cerebral Ischaemia-Reperfusion in Rats. Genes, 11(6), 681. PubMed
   
7. Stavchansky, V.V., Yuzhakov, V.V., Botsina, A.Y., Skvortsova, V.I., Bondurko, L.N., Tsyganova, M.G., Limborska, S.A., Myasoedov, N.F., & Dergunova, L.V. (2011). The effect of Semax and its C-end peptide PGP on the morphology and proliferative activity of rat brain cells during experimental ischemia: a pilot study. Journal of Molecular Neuroscience, 45(2), 177-185. PubMed
   
8. Tabbi, G., Giuffrida, A., Bonomo, R.P., Lanza, V., Levitskaya, N., Fazliyeva, R., Kazymov, M., Purrello, R., Magri, A., & Grasso, G. (2015). Semax, an ACTH4-10 peptide analog with high affinity for copper(II) ion and protective ability against metal induced cell toxicity. Journal of Inorganic Biochemistry, 147, 84-96. PubMed
   
9. Gusev, E.I., Skvortsova, V.I., Miasoedov, N.F., Nezavibat’ko, V.N., Zhuravleva, E.I., & Vanichkin, A.V. (1997). Effectiveness of semax in acute period of hemispheric ischemic stroke (a clinical and electrophysiological study). Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova, 97(6), 26-34. PubMed
   
10. Medvedeva, E.V., Dmitrieva, V.G., Limborska, S.A., Myasoedov, N.F., & Dergunova, L.V. (2017). Semax, an analog of ACTH(4-7), regulates expression of immune response genes during ischemic brain injury in rats. Molecular Genetics and Genomics, 292(3), 635-653. PubMed
    
11. Shadrina, M.I., Dolotov, O.V., Grivennikov, I.A., Slominsky, P.A., Andreeva, L., Inozemtseva, L.S., Limborska, S.A., & Myasoedov, N.F. (2001). Rapid induction of neurotrophin mRNAs in rat glial cell cultures by Semax, an adrenocorticotropic hormone analog. Neuroscience Letters, 308(2), 115-118. PubMed
    
12. Agapova, T.Y., Agniullin, Y.V., Shadrina, M.I., Shram, S.I., Slominsky, P.A., Limborska, S.A., & Myasoedov, N.F. (2007). Neurotrophin gene expression in rat brain under the action of Semax, an analogue of ACTH 4-10. Neuroscience Letters, 417(2), 201-205. PubMed
    
13. Myasoedov, N.F., Skvortzova, V.I., Nasonov, E.L., Zhuravleva, E.Y., Grivennikov, I.A., Arsenyeva, E.L., & Sukhanov, I.I. (1999). Investigation of mechanisms of neuroprotective effect of Semax in acute period of ischemic stroke. Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova, 5, 15-19. PubMed
    
14. Vyunova, T.V., Andreeva, L.A., Shevchenko, K.V., Shevchenko, V.P., Bobrov, M.Y., Bezuglov, V.V., & Myasoedov, N.F. (2019). An integrated approach to study the molecular aspects of regulatory peptides biological mechanism. Journal of Labelled Compounds and Radiopharmaceuticals, 62(11), 710-720. Link
    
15. Myasoedov, N.F. (2016). Innovative drugs: From basic research to production. Herald of the Russian Academy of Sciences, 86(3), 151-157. Link
    

All references open in new window. These citations are provided for educational and research purposes only. This information is not intended to diagnose, treat, cure, or prevent any disease. Semax is intended for laboratory research use only.